WO2008012635A3 - Amine derivatives useful as anticancer agents - Google Patents

Amine derivatives useful as anticancer agents Download PDF

Info

Publication number
WO2008012635A3
WO2008012635A3 PCT/IB2007/002065 IB2007002065W WO2008012635A3 WO 2008012635 A3 WO2008012635 A3 WO 2008012635A3 IB 2007002065 W IB2007002065 W IB 2007002065W WO 2008012635 A3 WO2008012635 A3 WO 2008012635A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
anticancer agents
amine derivatives
derivatives useful
Prior art date
Application number
PCT/IB2007/002065
Other languages
French (fr)
Other versions
WO2008012635A2 (en
Inventor
Matthew Stephen Corbett
Goss Stryker Kauffman
Kevin Daniel Freeman-Cook
Blaise Scott Lippa
Michael Joseph Luzzio
Joel Morris
Original Assignee
Pfizer Prod Inc
Matthew Stephen Corbett
Goss Stryker Kauffman
Kevin Daniel Freeman-Cook
Blaise Scott Lippa
Michael Joseph Luzzio
Joel Morris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Matthew Stephen Corbett, Goss Stryker Kauffman, Kevin Daniel Freeman-Cook, Blaise Scott Lippa, Michael Joseph Luzzio, Joel Morris filed Critical Pfizer Prod Inc
Publication of WO2008012635A2 publication Critical patent/WO2008012635A2/en
Publication of WO2008012635A3 publication Critical patent/WO2008012635A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula (II), and to pharmaceutically acceptable salts and solvates thereof. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula (I). The invention also relates to methods of making the compounds of formula (I).
PCT/IB2007/002065 2006-07-26 2007-07-13 Amine derivatives useful as anticancer agents WO2008012635A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82044106P 2006-07-26 2006-07-26
US60/820,441 2006-07-26

Publications (2)

Publication Number Publication Date
WO2008012635A2 WO2008012635A2 (en) 2008-01-31
WO2008012635A3 true WO2008012635A3 (en) 2008-05-08

Family

ID=38963178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002065 WO2008012635A2 (en) 2006-07-26 2007-07-13 Amine derivatives useful as anticancer agents

Country Status (7)

Country Link
AR (1) AR062050A1 (en)
CL (1) CL2007002188A1 (en)
GT (1) GT200700062A (en)
PE (1) PE20080689A1 (en)
TW (1) TW200817408A (en)
UY (1) UY30499A1 (en)
WO (1) WO2008012635A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
PL2049500T3 (en) 2006-07-06 2012-02-29 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA99284C2 (en) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані P70 s6 kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (en) 2007-07-05 2015-03-11 阵列生物制药公司 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2394759T3 (en) 2008-01-08 2013-02-05 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN101965347B (en) 2008-01-09 2013-01-02 阵列生物制药公司 Pyrazolopyridines as kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CL2009001152A1 (en) * 2008-05-13 2009-10-16 Array Biopharma Inc Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
AR074072A1 (en) 2008-11-11 2010-12-22 Lilly Co Eli COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
DE102009005193A1 (en) * 2009-01-20 2010-07-22 Merck Patent Gmbh Novel heterocyclic compounds as MetAP-2 inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
EP3461824B1 (en) 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
RU2017127088A (en) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. COMBINATION OF CHECKPOINT KINASE 1 INHIBITORS AND WEE 1 KINASE INHIBITORS
JP5927201B2 (en) 2010-12-16 2016-06-01 カルチャン リミテッド ASK1-inhibited pyrrolopyrimidine derivatives
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP6147246B2 (en) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Combinations of AKT and MEK inhibitor compounds and methods of use
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
PL2755958T3 (en) * 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
AR091273A1 (en) 2012-06-08 2015-01-21 Biogen Idec Inc PYRIMIDINYL TIROSINE KINASE INHIBITORS
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (en) 2013-04-19 2019-02-01 英塞特控股公司 Bicyclic heterocycle as an FGFR inhibitor
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
RU2019104758A (en) 2016-07-21 2020-08-21 Байоджен Ма Инк. SUCCINATE FORMS AND COMPOSITIONS OF BRUTON TYROSINE KINASE INHIBITORS
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
AU2019262195A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CR20200591A (en) 2018-05-04 2021-03-31 Incyte Corp Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (en) 2019-10-14 2022-07-19 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (en) 2019-12-04 2022-09-30 Incyte Corp DERIVATIVES OF AN FGFR INHIBITOR
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006046024A1 (en) * 2004-10-25 2006-05-04 Astex Therapeutics Limited Ortho- condensed pyridine and pyrimidine derivatives (e. g. purines) as protein kinases inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006046024A1 (en) * 2004-10-25 2006-05-04 Astex Therapeutics Limited Ortho- condensed pyridine and pyrimidine derivatives (e. g. purines) as protein kinases inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors

Also Published As

Publication number Publication date
TW200817408A (en) 2008-04-16
UY30499A1 (en) 2008-02-29
GT200700062A (en) 2008-08-08
CL2007002188A1 (en) 2008-02-01
AR062050A1 (en) 2008-08-10
PE20080689A1 (en) 2008-06-14
WO2008012635A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
UA89123C2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200728307A (en) Novel spirochromanone derivatives
EA200870423A1 (en) DERIVATIVES OF TRIAZOLPYRAZINES APPLICABLE AS ANTI-CANCER AGENTS
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
TW200833675A (en) Nicotinamide derivatives
WO2006053342A3 (en) Integrin antagonists useful as anticancer agents
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
MX2009004096A (en) Talarazole metabolites.
MX2008002061A (en) Thiazolyl piperidine derivatives.
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007135527A3 (en) Benzimidazolyl compounds
MX2009009238A (en) Novel phosphodi esterase inhibitors.
TW200745066A (en) Novel PTP1B inhibitors
WO2006116733A3 (en) Protein kinase inhibitors
NO20076196L (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidemic conditions
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200626158A (en) Naphthaline derivatives
WO2007017728A3 (en) Novel heterocyclic compounds
TW200745033A (en) Oxindole derivative as feeding control agent
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789508

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789508

Country of ref document: EP

Kind code of ref document: A2